Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InfuSystem’s business might look straightforward—renting and servicing infusion pumps—but its SEC disclosures reveal a maze of reimbursement rules, device safety updates and segment revenue math. Finding the oncology pump utilisation rate or the margin on biomedical repairs inside a 300-page report can slow even seasoned analysts.
That’s why this page brings every InfuSystem SEC filing explained simply. Stock Titan’s AI surfaces key details within minutes, whether you need an InfuSystem annual report 10-K simplified or an InfuSystem quarterly earnings report 10-Q filing. Ask natural questions like “What does InfuSystem report about payer mix?” and our algorithms point you to the exact footnote. Real-time alerts ensure InfuSystem Form 4 insider transactions are flagged the moment executives trade.
Use the full range of documents without scrolling through EDGAR:
- Form 4: Track InfuSystem insider trading Form 4 transactions and receive InfuSystem Form 4 insider transactions real-time notifications.
- 10-Q: Get concise InfuSystem earnings report filing analysis with segment breakouts and cash-flow highlights.
- 10-K: Understand long-term pump fleet commitments via understanding InfuSystem SEC documents with AI.
- 8-K: See InfuSystem 8-K material events explained when new payer contracts or device recalls hit the wire.
- DEF 14A: Review the InfuSystem proxy statement executive compensation tables without digging through PDFs.
Whether you’re monitoring InfuSystem executive stock transactions Form 4 before contract renewals or benchmarking quarter-over-quarter repair revenue, Stock Titan delivers AI-powered summaries, expert context and continuous updates—so you can act with confidence instead of paging through documents.
InfuSystem Holdings, Inc. furnished an Investor Presentation dated November 13, 2025 under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1.
The materials are expressly furnished, not filed, and therefore are not subject to Section 18 liabilities and are not incorporated by reference into other Securities Act or Exchange Act filings.
InfuSystem Holdings (INFU): AWM Investment Company filed Amendment No. 11 to Schedule 13G reporting beneficial ownership of 561,656 shares of InfuSystem common stock, representing 2.8% of the class.
AWM reports sole voting and sole dispositive power over these shares. The filing states AWM acts as investment adviser to Special Situations Life Sciences Fund, L.P., which holds the shares. The certification indicates the securities were acquired and are held in the ordinary course of business and not to change or influence control. Item 5 confirms ownership of 5 percent or less of the class. The date of the event requiring the filing is 09/30/2025.
InfuSystem Holdings, Inc. announced that President and CEO Carrie Lachance and CFO Barry Steele will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025.
The company furnished this update under Item 7.01 (Regulation FD). A related press release was provided as Exhibit 99.1 and is designated as furnished, not filed, under the Exchange Act.
InfuSystem Holdings (INFU) reported higher Q3 results. Net revenues were $36,488k, up from $35,320k. Gross profit rose to $20,820k and operating income reached $3,811k. Net income was $2,259k, or $0.11 per diluted share, compared with $1,807k, or $0.08 per share, a year ago.
For the first nine months, net revenues were $107,206k versus $101,013k, with net income of $4,591k ($0.22 diluted). Cash provided by operating activities was $17,282k, reflecting stronger cash generation. The company repurchased $8,563k of common stock year-to-date under its $20,000k authorization.
Segment mix in Q3 showed Patient Services external revenue of $22,363k and Device Solutions external revenue of $14,125k. InfuSystem acquired certain assets of Apollo Medical Supply for $1,412k to expand wound care within Patient Services. The revolving credit facility had $21,360k outstanding and $53,640k available, with maturity extended to July 15, 2030.
InfuSystem Holdings (INFU) furnished its third-quarter 2025 results via an 8-K. The company reported that a press release detailing Q3 2025 financial results was provided under Item 2.02 and attached as Exhibit 99.1. The company states this information is furnished, not filed, under the Exchange Act, and therefore not subject to Section 18 liabilities. The filing also includes the Inline XBRL cover page file as Exhibit 104.
InfuSystem Holdings, Inc. announced it will disclose its third‑quarter 2025 financial results on November 4, 2025 before the market opens. The company will host a conference call for investors the same day at 9:00 a.m. Eastern Time.
The related press release is furnished as Exhibit 99.1.
InfuSystem Holdings (INFU) insider transaction: EVP-Chief HR Officer Jerod Funke reported RSU settlement on October 9, 2025. Restricted stock units converted into common stock on a one-for-one basis, resulting in 12,500 shares acquired at $0 per share via code “M”. To cover taxes, the issuer withheld 3,669 shares at $9.61 under code “F”.
After these transactions, Funke directly owned 18,662 shares of InfuSystem common stock.
Insider filing for Carrie Lachance, President and CEO of InfuSystem Holdings (INFU). On 09/23/2025, 50,000 performance-based restricted stock units granted May 16, 2025, vested and were settled into common stock. The issuer withheld 19,675 shares to cover tax withholding at an indicated value of $10.22 per share, leaving the reporting person with 232,174 shares beneficially owned after the transactions. The Form 4 shows the reporting person held 201,849 shares before the vesting, which increased to 251,849 upon settlement then decreased due to withholding. This filing documents routine equity compensation vesting and related tax withholding by an executive who is also a director.
FAQ
What is the current stock price of Infusystem Hld (INFU)?
What is the market cap of Infusystem Hld (INFU)?
